Abstract 1636P
Background
Soft-tissue sarcomas (STSs) has been treated with similar patterns of care but represent an heterogeneous group of diseases. Recently new drugs came out with specific interest for selected histotype STSs. The primary aim of this retrospective study was to describe the outcome, prognostic factors and treatment for patients with metastatic synovial sarcoma (SS) included in the French NETSARC database.
Methods
In this retrospective study, pediatric and adult patients, with a metastatic SS were registered. Patient and tumor characteristics were collected from the national network NETSARC database (http://netsarc.sarcomabcb.org).
Results
From 15 July 1980 to 31 December 2019, 387 patients were included; among them 12.9% of children and adolescent and young adult. The median age was 42 years [30-52]. Metastases were synchronous (cohort 1) or metachronous (cohort 2) for 72 (18.6%) and 315 (81.4%) patients respectively. Sites of origin were pelvis, limb and thorax for respectively 136 (35.1%), 127 (32.8%) and 71 (18.3%) patients. Lung was the first location of metastases for 74.4% patients, followed by bone and pleura. Initial surgery was performed for 41 (56.9%) patients in cohort 1 and outside a reference center for 48.8% of them. The R0 rate was 19.4%. Patients in cohort 2 were operated for 95.2% and in a reference center for 110(36.7%) patients with a R0 rate of 37.8%. In cohort 2, at pre-operative setting, 68.3% and 60.6% patients received radiotherapy and chemotherapy respectively. Local treatment was performed for 51%, 22.2% and 8.9% patients respectively for their first, second, and third metastatic relapse. Chemotherapy was administrated with a median number of 3 lines [2-4]. Median follow up from metastatic diagnosis was 18 months [9.5-33]. Median time to relapse for cohort 2 was 20 months [11-32.5]. Median survival at metastatic setting was similar for the two cohorts: 18 months [11.8-26.5] for cohort 1 and 18 months [10-31.5] for cohort 2. Eighty-two (21.2%) patients were alive. Five-year survival was 8%. Results from prognostic univariate and multivariate analyses and tables will be reported at this meeting.
Conclusions
To our knowledge, this is the largest study of metastatic synovial sarcoma.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Camille Moreau-Bachelard.
Funding
Has not received any funding.
Disclosure
O. Mir: Honoraria (self), Travel/Accommodation/Expenses: amgen; Honoraria (self), Honoraria (institution): Astra-zeneca; Honoraria (self), Research grant/Funding (institution): Bayer; Honoraria (institution): bristol Myers-Squibb; Honoraria (self), Research grant/Funding (institution): Eli-lilly; Honoraria (self), Honoraria (institution), Shareholder/Stockholder/Stock options: Ipsen; Honoraria (self): lundbeck; Honoraria (self): MSD; Honoraria (self), Honoraria (institution): Novartis; Honoraria (self), Honoraria (institution), Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Pfizer; Honoraria (self), Honoraria (institution), Travel/Accommodation/Expenses: Roche; Honoraria (self), Speaker Bureau/Expert testimony: Servier; Honoraria (self): Vifor pharma; Honoraria (institution), Advisory/Consultancy, Research grant/Funding (institution): Blueprint medicines; Honoraria (institution): PharmaMar; Research grant/Funding (institution): Agios Pharmaceuticals; Research grant/Funding (institution): Epizyme; Shareholder/Stockholder/Stock options: Amplitude Surgical; Shareholder/Stockholder/Stock options: Transgene. C.M. Chevreau: Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: BMS; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Ipsen; Honoraria (self), Advisory/Consultancy: Novartis. All other authors have declared no conflicts of interest.